18 September 2020 : Database Analysis
Development and Validation of a Novel Immune-Gene Pairs Prognostic Model Associated with CTNNB1 Alteration in Hepatocellular Carcinoma
Junyu Huo1ABCDEF, Liqun Wu1AEF*, Yunjin Zang1AEDOI: 10.12659/MSM.925494
Med Sci Monit 2020; 26:e925494
Table 3 The chi-square test of the relation between risk score and clinical features in ICGC.
| Clinical feature | Risk score | χ2 | P | |
|---|---|---|---|---|
| High risk n(%) | Low risk n(%) | |||
| Gender | 0.538 | 0.463 | ||
| Male | 47 (27.81%) | 122 (72.19%) | ||
| Female | 20 (32.79%) | 41 (67.21%) | ||
| Age | 0.382 | 0.537 | ||
| >65 | 39 (27.66%) | 102 (72.34%) | ||
| ≤65 | 28 (31.46%) | 61 (68.54%) | ||
| Stage | 30.071 | 0.001 | ||
| I–II | 23 (16.20%) | 119 (83.80%) | ||
| III–IV | 44 (50.00%) | 44 (50.00%) | ||
| Prior malignancy | 0.562 | 0.453 | ||
| Yes | 7 (23.33%) | 23 (76.67%) | ||
| No | 60 (30.00%) | 140 (70.00%) | ||